Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Toviaz® (fesoterodine fumarate) – New indication
June 17, 2021 - The FDA approved Pfizer’s Toviaz (fesoterodine fumarate), for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older with a body weight greater than 25 kg.
